What factors may increase the risk of impaired injection-site healing with Imlygic (talimogene laherparepvec)?

Imlygic (talimogene laherparepvec) may increase the risk of impaired injection-site healing in patients with underlying risk factors, such as previous radiation at the injection site or lesions in poorly vascularised areas.